期刊文献+

5-氟尿嘧啶磁性固体脂质纳米粒制备工艺优化研究 被引量:2

Study on Optimization of 5-Fluorouracil Magnetic Solid Lipid Nanoparticles
下载PDF
导出
摘要 为提高5-氟尿嘧啶(5-FU)制剂的疗效,降低毒副作用,以单硬脂酸甘油酯为载体,氢化大豆卵磷脂、泊洛沙姆为乳化剂,磁性纳米四氧化三铁为磁体,采用复乳-溶剂挥发法制备5-氟尿嘧啶磁性固体脂质纳米粒(5-FU-MSLN).以包封率为考察指标,通过单因素实验和正交设计对制备工艺进行优化,所制备的5-FU-MSLN包封率为58.35%.用透射电镜观察,磁性固体脂质纳米粒外观形态圆整,粒径分布均匀;在倒置的显微镜下观察,磁性固体脂质纳米粒体外磁响应性良好,实验结果表明,5-FU-MSLN是有希望的静脉给药靶向制剂. To improve the therapeutic efficacy and reduce the toxicity of 5-Fluorouracil(5-FU),5-Fluorouracil magnetic solid lipid nanoparticles(5-FU-MSLN) were prepared with a W/O/W double emulsion solvent evaporation technique,using monostearin as the carrier,hydrogenated soybean lecithin and poloxamer as emulsifier,magnetic Fe3O4 nanoparticles as magnets.With the index of encapsulation efficiency,the preparation process was optimized by single-factor test and orthogonal test.As a result,the encapsulation efficiency of 5-FU-MSLN was 58.35%.TEM presented 5-FU-MSLN as spherical particles,evenly distributed;5-FU-MSLN were observed under the inverted microscope,of which vitro magnetic responsiveness was good.Such magnetic solid lipid nanoparticles seem appropriate for vascular administration followed by drug targeting.
出处 《郑州大学学报(工学版)》 CAS 北大核心 2010年第3期16-19,共4页 Journal of Zhengzhou University(Engineering Science)
基金 郑州市科技攻关计划资助项目(083SGYS33261-1)
关键词 5-氟尿嘧啶 磁性固体脂质纳米粒 工艺优化 包封率 5-Fluorouracil magnetic solid lipid nanoparticle optimization encapsulation rate
  • 相关文献

参考文献10

二级参考文献26

  • 1陈江飞,张典瑞,张学顺,邢洁.苦参碱固体脂质纳米粒的试制及物相分析[J].中国医药工业杂志,2005,36(4):214-217. 被引量:12
  • 2沈正荣,朱家蕙,吴兰亭,肖银林,程敬亮,吴自伦,李树新.5-氟尿嘧啶聚乳酸微球制备及体内外释药特性的研究[J].中国医药工业杂志,1995,26(7):306-309. 被引量:22
  • 3[1]Muller RH, Mehnert W, Lucks JS, et al. Solid lipid nanoparticles(SLN)-an alternative colloidal carrier system for controlled drug delivery [J]. Eur J Pharm Biopharm, 1995,41(1):62-69.
  • 4[2]De Vringer T, de Ronde HAG. Preparation and structure of a water-in-oil cream containing lipid nanoparticles [J]. J Pharm Sci, 1995,84(4):466-472.
  • 5[3]Schwarz C, Mehnert W, Lucks JS, et al. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization [J]. J Controlled Release, 1994,30(1):83-96.
  • 6[4]Yang SC, Lu LF, Cai Y, et al. Body distribution in mice of intraveneously injected camptothecin solid lipid nanoparticles and targeting effect on brain [J]. J Controlled Release, 1999,59(3):299-307.
  • 7[5]Annette M, Schwarz C, Mehnert W. Solid lipid nanoparticles(SLN) for controlled drug delivery-drug release and release mechanism [J]. Eur J Pharm Biopharm, 1998,45(2):149-155.
  • 8[6]Gasco MR. Method for producing solid lipid microspheres having a narrow size distribution [P]. US Pat: 5250236,1993-10-05.
  • 9[7]Su DS. Studies on the physical properties of fat emulsion of anticancer drug [J]. J Shenyang Coll Pharm (沈阳药科大学学报), 1999,8(1):1-3.
  • 10Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery.Ⅱ. Drug incorporation and physicochemical characterize- ation [J]. J Microencapsulation, 1999,16 ( 2 ) : 205-213

共引文献53

同被引文献50

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部